Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis
2013 · The Oncologist · 93 citations
https://doi.org/10.1634/theoncologist.2012-0350
F
Fernando Bazán
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
125
Papers
8.5K
Citations
26
h-index
42
i10-index
Fernando Bazán is an academic researcher from Reykjavík University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & PARP inhibition in cancer therapy. The author has an h-index of 26, co-authored 107 publications.
Papers by this author
worksDiscordance in early breast cancer for tumour grade, Estrogen Receptor, Progesteron Receptors and Human Epidermal Receptor-2 status between core needle biopsy and surgical excisional primary tumour
2011 · The Breast · 74 citations
https://doi.org/10.1016/j.breast.2010.12.007
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
2021 · European Journal of Cancer · 31 citations
https://doi.org/10.1016/j.ejca.2021.03.029
In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?
2015 · The Oncologist · 23 citations
https://doi.org/10.1634/theoncologist.2014-0198
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
2019 · BMC Cancer · 18 citations
https://doi.org/10.1186/s12885-019-6228-6
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
2023 · Breast Cancer Research and Treatment · 16 citations
https://doi.org/10.1007/s10549-023-07165-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat